SELLAS Life Sciences Group, Inc

SLSNASDAQ · Pharmaceutical Preparations

Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

201.9M

on 2026-06-30, from 56.3M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

No limit

S-3ASR of 2026-03-20. An automatic shelf: the form sets no dollar limit. Sales under the at-the-market programme filed with it are not stated apart. S-3ASR ↗

$150.0M

TD Securities (USA), agreement of 2026-03-20. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗

Warrants

9.71M

Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $1.70. 10-Q ↗

Cash

19.5 quarters

$138.3M on 2026-06-30 ÷ $7.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-10-24	Public offering	not read	$1.535	$31.0M	424B5 ↗